
Combined photodynamic therapy with chloroaluminum phthalocyanine and doxorubicin nanoemulsions in breast cancer model
2021; Elsevier BV; Volume: 218; Linguagem: Inglês
10.1016/j.jphotobiol.2021.112181
ISSN1873-2682
AutoresÁgata Silva Cabral, Ellen Cristina Rivas Leonel, Natália Maria Cândido, Henrique Luís Piva, Maryanne Trafani de Melo, Sebastião Roberto Taboga, Paula Rahal, Antônio Cláudio Tedesco, Marília Freitas Calmon,
Tópico(s)Porphyrin and Phthalocyanine Chemistry
ResumoBreast cancer is the most common neoplasm among women but thanks to innovative therapies, patients' prognosis has considerably improved. In this aspect, nanotechnology has been applied for cancer therapy aiming to reduce its usual side effects. In this study we aimed to evaluate the effects of nanoemulsions containing photosensitizer and chemotherapeutic agents associated with photodynamic therapy in a breast cancer in vivo model. Our results showed that synergistic treatments in which chloroaluminum phthalocyanine (NE-Pc) administered together with Doxorubicin (Dox) in the presence of laser irradiation (NE-PcDoxo + PDT) led to a reduction of 4 T1 induced breast cancer in mice, decline of tumor VEGF expression, increase in Caspase-3 expression, tissue necrosis and massive decrease in proliferative cells, as shown by Ki67 immunostaining. Furthermore, this associated treatment induced overexpression of apoptotic genes ABL1, CD70, CRADD, FASL, and NME5 and a reduction in expression of anticancer drug target genes CDK2, ERBB2, FIGF, IGF2, PARP4 and PGR. These results validate this treatment as a promising alternative to improve the currently applied anticancer strategies.
Referência(s)